Book a free consultation
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationIf this is where you are
Newly diagnosedReports arriving, no plan yetAlready tested elsewhereYou have results you cannot readOn treatment nowYou want to know it is workingOr
Finished treatmentWatching for anything left behindWorried about familyInherited risk, and relativesWanting a second opinionA decision you are unsure aboutDecide
Blueprint CareThe flagship decision report and a dedicated clinical teamSignalOne free question answered on WhatsApp within four hoursNavigationRecords you already have, turned into a clarity timelineDecipherInterpretation of sequencing already done elsewhereTest: solid tumour
All Signature testsEvery panel compared, side by sideSignature STb33 genes from a blood drawSignature STb O118 genes from blood, including fusionsSignature STb O+523 genes, with TMB, MSI and pharmacogenomicsSignature STt OComprehensive profiling from a tissue blockTest: blood cancer
Signature BML+Myeloid, 600+ genes, with MDS and MPN overlapSignature BLL+Lymphoid, 600+ genes, with Philadelphia-like detectionSignature CustomDesigned around one question when neither family fitsMonitor
SentinelSerial monitoring while treatment is runningSentinel SolidctDNA monitoring for solid tumoursClearMolecular residual disease surveillanceClear SolidTumour-informed surveillance for solid tumoursClear BloodResidual disease surveillance after blood cancer treatmentProtect
HeritageInherited risk, assessed properlyHeritage CoreA broad inherited-risk assessmentHeritage AdhocFocused testing for named relativesCancer DictionaryWhat is discussed in your specific cancerReference
Cancer DictionaryOne structured entry per cancer typeBiomarker LibraryOne page per marker, in plain languagePatient ResourcesGlossary, guides and how to use themWatch, read and ask
Video LibraryShort explainers, captioned and translatedJourneysFour composites showing how a decision gets madeCase studiesNine situations and the test that fits eachFAQThe questions we are asked mostTurn existing data into a decision
Already tested elsewhere? We turn data you already have into a full Blueprint Care decision, with no new sequencing.
Decipher turns data you already have into a full Blueprint Care decision, with no new sequencing. We run your existing genomic report through our engine and KPCIRC sign-out.
You get the ranked plan, the trial matches, the biosimilar and access mapping, and the six intelligence layers, built on the test you already paid for.

A recent comprehensive report, but no decision attached.
A second, more thorough interpretation and a signed plan.
No cost or delay where re-sequencing is not needed.
| Decipher | Decipher Plus | |
|---|---|---|
| What we do | Interpret your existing data in full | Interpret, and fill only the missing pieces |
| New testing | None | A targeted top-up only, such as TMB, MSI or PGx |
| Best when | Your report is comprehensive | Your report is missing markers |
| Output | Full Blueprint Care report | Full Blueprint Care report |
Send us your existing genomic results.
We identify whether anything essential is missing.
Decipher reads as-is. Plus adds the gaps first.
You receive a full, signed decision.
We will not present an incomplete picture as a complete one.
Decipher can only interpret what your existing data contains. If your report is missing markers we will recommend Decipher Plus rather than fill the gap with guesswork.
Being clear about our limits
| Term | What it means |
|---|---|
| Interpretation | Turning an existing variant list into a ranked, evidenced decision. |
| Top-up | A small, targeted test to fill one missing marker such as TMB, MSI or PGx. |
| MTB | Molecular tumour board, the licensed panel that signs the final decision. |
| VUS | Variant of uncertain significance, a change whose meaning is not yet clear. |
Decipher and Decipher Plus is a genomic (DNA-based) test for use by qualified healthcare professionals. It supports clinical judgement, it does not replace it, and it must be read alongside your full clinical history and applicable guidelines.
Regulatory status (India). Registration of our genomic tests as in-vitro diagnostic (IVD) medical devices with CDSCO is in progress, with the IVD class pending. Sequencing and variant calling are done by an accredited laboratory partner holding NABL (ISO 15189), CAP and CLIA accreditation, following ACMG/AMP/ASCO/CAP guidelines and a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.
Take the next step
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationCommission your decision report and a dedicated clinical team.
Explore Blueprint CareSignal replies to your first question within four hours, at no cost.
Start with Signal